Overview of Dr. McGuinn
Dr. Catherine McGuinn is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Queens. She received her medical degree from New York University Grossman School of Medicine and has been in practice 12 years. Dr. McGuinn accepts several types of health insurance, listed below. She is one of 135 doctors at New York-Presbyterian Hospital and one of 6 doctors at New York-Presbyterian Queens who specialize in Pediatric Hematology & Oncology. She has more than 10 publications and over 500 citings.
Office
525 E 68th St
# Pediatri
New York, NY 10065
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 2008 - 2011
- New York Presbyterian Hospital (Cornell Campus)Residency, Pediatrics, 2005 - 2008
- New York University School of MedicineClass of 2005
Certifications & Licensure
- NY State Medical License 2007 - 2026
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Hemophilia Inhibitor Previously Untreated Patient Study Start of enrollment: 2011 Jul 01
- Safety and Efficacy of Eltrombopag at Escalated Doses Start of enrollment: 2013 Feb 01
- ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Start of enrollment: 2013 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsTreatment of newly diagnosed severe aplastic anemia in children: Evidence-based recommendations.Kristin A Shimano, Jennifer A Rothman, Steven W Allen, Paul Castillo, Jill L O de Jong
Pediatric Blood & Cancer. 2024-08-01 - 1 citationsTreatment of relapsed/refractory severe aplastic anemia in children: Evidence-based recommendations.Kristin A Shimano, Ghadir Sasa, Larisa Broglie, Nicholas J Gloude, Kasiani Myers
Pediatric Blood & Cancer. 2024-08-01 - 3 citationsA review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency.Jeanette Payne, Glaivy Batsuli, Andrew D Leavitt, Mary Mathias, Catherine E McGuinn
Haemophilia. 2022-07-01
Press Mentions
- A Grandpa's Hope for Hemophilia Cure Leads Him to Gene Therapy Clinical TrialNovember 16th, 2018
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS California CaliforniaCare HMO
BCBS California PowerSelect HMO
BCBS California PPO
BCBS Illinois PPO
BCBS Texas BlueChoice
Blue Shield CA Local Access Plus HMO
Blue Shield California HMO
Blue Shield California PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOFirst Health PPO
Great West PPO
Health Net California Large Group PPO
Health Net HMO - Employer Group
Healthfirst New York
HIP of New York - Select PPO
Multiplan PHCS PPO
Multiplan PHCS PPO - Kaiser
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
Pacificare HMO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: